drugset / Trial / NCT00816478

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

NCT00816478

Phase 1 Terminated 15 enrolled Northwell Health
NaSingle-groupOpen-labelTreatment

Summary

This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.

Timeline

Start
2008-12
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Galactose Diagnostic / imaging agent 0.2 g/kg Oral